MERRF Classification: Implications for Diagnosis and Clinical Trials

Area of Science:

• Genetics
• Neurology
• Mitochondrial Diseases

Background:

• Myoclonic epilepsy with ragged-red fibers (MERRF) exhibits etiological heterogeneity, complicating classification based on clinical symptoms alone.
• Standardized approaches are crucial for precise MERRF definition, aiding patient diagnosis, stratification, and clinical trial development.

Purpose of the Study:

• To apply contemporary criteria for classifying variants associated with MERRF.
• To evaluate the strength of evidence for gene-disease associations in MERRF.

Main Methods:

• Conducted a systematic literature and database search.
• Assessed gene-disease relationships using modified Smith criteria.
• Evaluated MERRF-associated variants with modified Yarham criteria.

Main Results:

• Gene-disease association supported for two MT-tRNAs and POLG.
• Definitive evidence for MT-TK as a MERRF gene; strong evidence for MT-TL1 and POLG.
• Functional assays critical for classifying mtDNA variants; in silico analysis showed limited utility for MT-tRNA variants.
• Reclassified several previously pathogenic mtDNA variants as neutral using contemporary criteria.

Conclusions:

• MERRF is predominantly an MT-TK disease, responsible for approximately 90% of cases.
• Myoclonic epilepsy is the distinguishing clinical feature of MERRF among mitochondrial disorders.
• Standardized classification, rather than clinical phenomenology, enhances MERRF diagnosis and clinical trial design.